In a remarkable performance, a US-focused pharma formulations player has posted a profit CAGR of 155% over the past three years. This growth is highlighted by a recent quarter where profits more than doubled compared to the previous year.
The company's success is attributed to a strategic acquisition in the central nervous system (CNS) sector, which is expected to enhance its product offerings and market reach.
Additionally, the rising contribution from specialty products has played a significant role in driving profitability, positioning the company as a strong contender in the pharmaceutical market.